No price history available.
Key financial summary
Financials in ILA| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | ILAm | 0 | 0 | 0 | 0 | 0 | 0 | N/A | N/A |
| Operating profit | ILAm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | ILAm | -4 | -5 | -11 | -9 | -2 | -2 | N/A | N/A |
| EPS reported | ILA | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | ILA | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | ILA | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | ILA | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | ILAm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | ILAm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | ILAm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | ILA | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | ILA | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in ILA| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Grace Breeding Ltd, an agro-tech company, engages in the research and development in the area of biological substitutes for synthetic materials used in the fertilizer and growth promoter industries in Israel and internationally. The company also sells seeds. Its product portfolio includes Maoz, a biofertilizer that aids with photosynthesis; ProMagen, a combination of plant materials with anti-inflammatory properties for biotic stress tolerance; and ClimAid for abiotic stress tolerance. Grace Breeding Ltd was incorporated in 2015 and is based in Ramat Gan, Israel.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Grace Breeding Ltd. (GRAC.TA)
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
Grace Breeding Ltd, an agro-tech company, engages in the research and development in the area of biological substitutes for synthetic materials used in the fertilizer and growth promoter industries in Israel and internationally. The company also sells seeds. Its product portfolio includes Maoz, a biofertilizer that aids with photosynthesis; ProMagen, a combination of plant materials with anti-inflammatory properties for biotic stress tolerance; and ClimAid for abiotic stress tolerance. Grace Breeding Ltd was incorporated in 2015 and is based in Ramat Gan, Israel.